Short answer
Entrada Therapeutics, Inc. (TRDA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Entrada Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Corporate updates included alongside quarterly results
- Full financial figures and management commentary in Exhibit 99.1 пресс release
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 results show net loss $39.7M, or $0.94 per share, versus $44.1M, or $1.06, in Q3 2025
- Cash, equivalents and marketable securities fell to $193.0M from $295.7M, supporting operations into Q4 2027
- ELEVATE-44-201 Cohort 1 completed open-label dosing, with data expected by year-end 2026
- ELEVATE-45-201 Cohort 1 met favorable safety and tolerability objectives at 5 mg/kg, with no discontinuations
- Multiple catalysts remain scheduled through H1 2027, including ELEVATE-44-201 and ELEVATE-45-201 Cohort 2 data and Vertex’s VX-670 readout
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Entrada Therapeutics, Inc. 8-K filings
Get the next TRDA 8-K as it lands
Follow TRDA for push alerts, or ask the research agent what this filing means.